PSZ: Devices Detecting Influenza A, B, And C Virus Antigens
What it covers
An influenza virus antigen detection test system is a device intended for the qualitative detection of influenza viral antigens directly from clinical specimens in patients with signs and symptoms of respiratory infection.
FDA’s definition of product code PSZ, from the Product Classification database.
Recent clearances
| 510(k) | Device | Applicant | Decision | Type |
|---|---|---|---|---|
| K254262 | Sofia Influenza A+B FIA; Sofia RSV FIA; Sofia Strep A+ FIA | Ortho Clinical Diagnostics Inc. (QuidelOrtho) | Sep 4, 2026 | Dual Track |
| K252283 | Nano-Check Influenza A+B Test | Nano-Ditech Corporation | Jan 15, 2026 | Dual Track |
| K250398 | Innovita Flu A/B Antigen Rapid Test | Innovita (Tangshan) Biological Technology Co., Ltd. | Jul 3, 2025 | Traditional |
| K241188 | Acucy® Influenza A&B Test with the Acucy® 2 System | SEKISUI Diagnostics, LLC | Apr 18, 2025 | Dual Track |
| K232434 | BD Veritor System for Rapid Detection of Flu A+B CLIA Waived Kit | Bd | Dec 5, 2023 | Traditional |
| K223016 | BD VeritorTM System for Rapid Detection of Flu A+B CLIA-Waived Kit | Bd | Jan 27, 2023 | Traditional |
| K192719 | Osom Ultra Plus Flu A&B Test Kit | SEKISUI Diagnostics, LLC | Apr 3, 2020 | Dual Track |
| K191514 | CareStart Flu A&B Plus | Access Bio, Inc. | Feb 18, 2020 | Dual Track |
| K182001 | Acucy Influenza A&B Test with the Acucy System | SEKISUI Diagnostics, LLC | Dec 17, 2018 | Dual Track |
| K182157 | BioSign Flu A+B | Princeton BioMeditech Corp. | Sep 18, 2018 | Special |
Clearances by year
37 PSZ 510(k)s were cleared from 2011 to Oct 29, 2026. Days to decision run from the day FDA received the 510(k) to its decision, including time on hold.
| Year | Clearances | Median days to decision |
|---|---|---|
| 2026 (so far) | 2 | 213 |
| 2025 | 2 | 248 |
| 2023 | 2 | 118 |
| 2020 | 2 | 223 |
| 2018 | 5 | 28 |
| 2017 | 3 | 200 |
| 2016 | 3 | 29 |
| 2015 | 4 | 27 |
| 2014 | 1 | 29 |
| 2013 | 8 | 28 |
| 2012 | 2 | 79 |
| 2011 | 3 | 80 |
Who submits
15 applicants cleared a PSZ device since 2011. 97% of the clearances went to applicants in United States, then China (3%). By type: Special 57%, Traditional 27% and Dual Track 16%.
| Applicant | Clearances since 2011 |
|---|---|
| Becton, Dickinson and Company | 9 |
| Alere Scarborough, Inc. | 3 |
| Bd | 3 |
| Becton, Dickinson & CO | 3 |
| Princeton BioMeditech Corp. | 3 |
| Quidel Corporation | 3 |
| SEKISUI Diagnostics, LLC | 3 |
| Alere Scarborough, Inc D/B/A Binax, Inc. | 2 |
How FDA classifies it
Class II (special controls). The special controls for this device are:
(1) The device's sensitivity and specificity performance characteristics or positive percent agreement and negative percent agreement, for each specimen type claimed in the intended use of the device, must meet one of the following two minimum clinical performance criteria:
(i) For devices evaluated as compared to an FDA-cleared nucleic acid based-test or other currently appropriate and FDA accepted comparator method other than correctly performed viral culture method:
(A) The positive percent agreement estimate for the device when testing for influenza A and influenza B must be at the point estimate of at least 80 percent with a lower bound of the 95 percent confidence interval that is greater than or equal to 70 percent.
(B) The negative percent agreement estimate for the device when testing for influenza A and influenza B must be at the point estimate of at least 95 percent with a lower bound of the 95 percent confidence interval that is greater than or equal to 90 percent.
(ii) For devices evaluated as compared to correctly performed viral culture method as the comparator method:
(A) The sensitivity estimate for the device when testing for influenza A must be at the point estimate of at least 90 percent with a lower bound of the 95 percent confidence interval that is greater than or equal to 80 percent. The sensitivity estimate for the device when testing for influenza B must be at the point estimate of at least 80 percent with a lower bound of the 95 percent confidence interval that is greater than or equal to 70 percent.
(B) The specificity estimate for the device when testing for influenza A and influenza B must be at the point estimate of at least 95 percent with a lower bound of the 95 percent confidence interval that is greater than or equal to 90 percent.
(2) When performing testing to demonstrate the device meets the requirements in paragraph (b)(1) of this section, a currently appropriate and FDA accepted comparator method must be used to establish assay performance in clinical studies.
(3) Annual analytical reactivity testing of the device must be performed with contemporary influenza strains. This annual analytical reactivity testing must meet the following criteria:
(i) The appropriate strains to be tested will be identified by FDA in consultation with the Centers for Disease Control and Prevention (CDC) and sourced from CDC or an FDA-designated source. If the annual strains are not available from CDC, FDA will identify an alternative source for obtaining the requisite strains.
(ii) The testing must be conducted according to a standardized protocol considered and determined by FDA to be acceptable and appropriate.
(iii) By July 31 of each calendar year, the results of the last 3 years of annual analytical reactivity testing must be included as part of the device's labeling. If a device has not been on the market long enough for 3 years of annual analytical reactivity testing to have been conducted since the device received marketing authorization from FDA, then the results of every annual analytical reactivity testing since the device received marketing authorization from FDA must be included. The results must be presented as part of the device's labeling in a tabular format, which includes the detailed information for each virus tested as described in the certificate of authentication, either by:
(A) Placing the results directly in the device's § 809.10(b) of this chapter compliant labeling that physically accompanies the device in a separate section of the labeling where the analytical reactivity testing data can be found; or
(B) In the device's label or in other labeling that physically accompanies the device, prominently providing a hyperlink to the manufacturer's public Web site where the analytical reactivity testing data can be found. The manufacturer's home page, as well as the primary part of the manufacturer's Web site that discusses the device, must provide a prominently placed hyperlink to the Web page containing this information and must allow unrestricted viewing access.
(4) If one of the actions listed at section 564(b)(1)(A)-(D) of the Federal Food, Drug, and Cosmetic Act occurs with respect to an influenza viral strain, or if the Secretary of Health and Human Services (HHS) determines, under section 319(a) of the Public Health Service Act, that a disease or disorder presents a public health emergency, or that a public health emergency otherwise exists, with respect to an influenza viral strain:
(i) Within 30 days from the date that FDA notifies manufacturers that characterized viral samples are available for test evaluation, the manufacturer must have testing performed on the device with those viral samples in accordance with a standardized protocol considered and determined by FDA to be acceptable and appropriate. The procedure and location of testing may depend on the nature of the emerging virus.
(ii) Within 60 days from the date that FDA notifies manufacturers that characterized viral samples are available for test evaluation and continuing until 3 years from that date, the results of the influenza emergency analytical reactivity testing, including the detailed information for the virus tested as described in the certificate of authentication, must be included as part of the device's labeling in a tabular format, either by:
(A) Placing the results directly in the device's § 809.10(b) of this chapter compliant labeling that physically accompanies the device in a separate section of the labeling where analytical reactivity testing data can be found, but separate from the annual analytical reactivity testing results; or
(B) In a section of the device's label or in other labeling that physically accompanies the device, prominently providing a hyperlink to the manufacturer's public Web site where the analytical reactivity testing data can be found. The manufacturer's home page, as well as the primary part of the manufacturer's Web site that discusses the device, must provide a prominently placed hyperlink to the Web page containing this information and must allow unrestricted viewing access.
From 21 CFR 866.3328. Special controls are the requirements a 510(k) must show it meets.
Standards
21 CFR 866.3328 names no consensus standards. Check FDA’s recognized standards database, or ask which standards recent PSZ clearances declared.
Ask about PSZ
Questions about PSZ
What is FDA product code PSZ?
Product code PSZ, “Devices Detecting Influenza A, B, And C Virus Antigens” in FDA's classification database, is a Class II device type under 21 CFR 866.3328 (influenza virus antigen detection test system), reviewed by FDA's Microbiology panel. FDA's 510(k) database lists 73 clearances under PSZ, 37 of them since 2011.
How many 510(k) clearances are there under PSZ?
FDA’s 510(k) database listed 73 clearances under PSZ as of Oct 29, 2026, 37 of them decided since 2011; the most recent decision was Sep 4, 2026. The Predicate Finder searches the live database.
How long does FDA take to clear a PSZ 510(k)?
For the 4 PSZ clearances decided in the two years before Oct 29, 2026, the median time from FDA receiving the 510(k) to its decision was 213 days. That counts calendar days, including time the submission was on hold waiting for answers from the submitter.
Which companies have the most PSZ clearances?
Since 2011: Becton, Dickinson and Company (9), Alere Scarborough, Inc. (3), Bd (3), Becton, Dickinson & CO (3) and Princeton BioMeditech Corp. (3). 15 applicants have cleared a PSZ device in that time.